Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonavalent HPV Vaccine vs Gardasil in Healthy Women
NCT05668572Phase 3Unknown
- Sponsor
- Beijing Health Guard Biotechnology Inc.
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of KLWS-V502 in human papillomavirus infection (2 arms), sponsored by Beijing Health Guard Biotechnology Inc. Primary endpoints: Combined Incidence of HPV types 6/11/16/18/31/33/45/52/58-related high-grade diseases at 60 months and Combined incidence of specific HPV types related persistent infections for no less than 12 months and related diseases at 60 months. Status: unknown.
02
Drugs
KLWS-V502
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05668572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668572.